Inhibitory Effect of Gefitinib on the Proliferation of Lens Epithelial Cells

PURPOSE: To evaluate the effect of Gefitinib used for the treatment of non-small cell lung cancer on the proliferation of the lens epithelial cells and the activities of growth factors. METHODS: The cell samples were divided into a control group cultured in DMEM and three experimental groups. Group I was exposed to Gefitinib for 3 minutes; group II was exposed to growth factors; and for group III growth factors were added to each concentration of Gefitinib. MMT assays, BrdU staining and morphologically observations with a phase-contrast microscope were used to verify the degrees of cell proliferation. Western blot analysis was conducted to confirm the effects of Gefitinib on extracellular signal-regulated kinase phosphorylation and on type I collagen production. RESULTS: Lens epithelial cell proliferation in experimental group I was reduced to 76% and 56% for 1.00 micro M and 10.00 micro M of Gefitinib, respectively. Experimental group II showed a 140% increase in cell proliferation with EGF treatment. Experimental group III exhibited decreased lens epithelial cell proliferation with both EGF (86% and 66%), and TGF-beta2 (78% and 59%). BrdU staining demonstrated a significant decrease in cell proliferation in groups I and III exposed to more than 1.0 micro M Gefitinib, while group II showed an increase compared to the control group. Moreover, Western blot analysis revealed inhibiting effects on ERK phosphorylation and type I collagen production. CONCLUSIONS: In the culture of human lens epithelial cells, Gefitinib inhibited cell proliferation when used at a concentration above 1.00 (M for 3 minutes. Furthermore, the effects of EGF and TGF-beta2 were also inhibited.

The Vision and Satisfaction According to Postoperative Refractive Error after AMO Array(R) Multifocal Intraocular Lens Insertion

PURPOSE: To evaluate the visual outcome and satisfaction according to postoperative refractive error in patient with cataract surgery using AMO Array(R) multifocal intraocular lens. METHODS: According to postoperative refractive errors, 120 eyes (80 patients) were inserted the AMO Array(R) multifocal intraocular lens and were divided into three groups respectively: 28 eyes were myopic group (-0.50 ~ -1.50D), 74 eyes were emetropic group (-0.50 ~ +0.50D) and 18 eyes were hyperopic group (+0.50 ~ +1.50D). In each group, distant vision, near vision and contrast sensitivity test were measured. Also the patients were questioned on their satisfaction. RESULTS: Three months after the operation, the distance uncorrected visions of the myopic, emmetropic and hyperopic group were 0.42 +/- 0.23, 0.73 +/- 0.22, 0.36 +/- 0.28 and the near uncorrected visions were 0.47 +/- 0.18, 0.65 +/- 0.03, 0.41 +/- 0.14 in each. There were no difference in satisfaction, contrast sensitivity and glare visual acuity between three groups. CONCLUSIONS: In cataract surgery using the AMO Array(R) multifocal intraocular lens, we could get the best uncorrected visual acuity in emmetopic group. There were no difference in satisfaction and vision between myopic and hyperopic group. Thus, at the time of cataract operation, the multifocal intraocular lens power should be set on emmetropia in order to improve the vision and satisfaction.